Radcom Ltd. (NASDAQ:RDCM) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with -4.48% to $11.29. RADCOM Ltd. (RDCM) announced that pricing of its previously announced underwritten public offering of 1,818,182 ordinary shares at an offering price of $11.00 per share. Gross proceeds from the offering are expected to be approximately $20 million, before underwriting discounts and commissions and other offering expenses. In connection with the offering, RADCOM has also granted the underwriters a 30-day option to purchase up to an additional 272,727 ordinary shares.
RADCOM’S largest shareholder, Zohar Zisapel, has agreed to purchase 200,000 ordinary shares offered in this offering from the underwriters at the public offering price. The offering is expected to close on or about May 25, 2016, subject to customary closing conditions. RADCOM intends to use the net proceeds of the offering for general corporate purposes, which may include financing its operations, capital expenditures and business development. The share price of RDCM attracts active investors, as stock price of week volatility recorded 7.07%. The stock is going forward to its 52-week low with 27.14% and lagging behind from its 52-week high price with -35.85%.
Pfizer Inc. (NYSE:PFE) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.08% to close at $33.74 with the total traded volume of 34.39 Million shares. Pfizer Inc. (PFE) revealed that European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for TRUMENBA for review. TRUMENBA has been developed for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10 years and older. The acceptance marks the beginning of the regulatory review process for this vaccine in the EU.
The senior VP and head of Vaccine Research and Development for Pfizer Inc., Kathrin Jansen stated that the EMA’s acceptance of TRUMENBA’s Marketing Authorization Application brings them one step closer to fighting this uncommon yet life-threatening disease worldwide, by helping to protect adolescents and adults who are at risk to contract meningococcal disease caused by serogroup B. “At Pfizer we are committed to providing innovative vaccines that help people live the longest, healthiest lives possible.” The firm has institutional ownership of 76.50%, while insider ownership included 0.10%. Its price to sales ratio ended at 4.07. PFE attains analyst recommendation of 2.20 with week performance of 1.66%.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) [Trend Analysis] moved up reacts as active mover, shares an increase 4.61% to traded at $27.47 and the percentage gap between open changing to regular change was -0.69%. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) announced that it has received a notice of default from the trustee under one of its senior note indentures as a result of the delay in Valeant filing its Form 10-Q for the period ended March 31, 2016. The notice of default does not result in the acceleration of any of Valeant’s indebtedness.
Under its senior note indenture, Valeant has 60 days from the receipt of the notice to file the Form 10-Q, which will cure the default in all respects. As announced on May 9, 2016, Valeant expects to file the Form 10-Q with the Securities and Exchange Commission and the Canadian Securities Regulators on or before June 10, 2016, which would be well in advance of the 60-day cure date of July 18, 2016. The firm’s current ratio calculated as 1.00 for the most recent quarter. The firm past twelve months price to sales ratio was 0.92 and price to cash ratio remained 16.02. As far as the returns are concern, the return on equity was recorded as -4.60% and return on investment was 3.70% while its return on asset stayed at -0.60%. The firm has total debt to equity ratio measured as 5.26. The firm has 20-Day Simple Moving Average has